Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial - El-Khoueiry, A B; Sangro, B; Yau, T (Lancet (London, England), 2017)
et al.